Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eduard Ghersin

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Behavioral Medicine (Washington, D.C.)|November 15, 2024
The Role of Intersectional Stigma in Coronary Artery Disease Among Cisgender Women Aging with HIVTiffany R Glynn, Michaela E Larson, Maria Bernal, et al.
JAMA|November 3, 2012
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trialJoshua M Hare, Joel E Fishman, Gary Gerstenblith, et al.
Circulation Research|January 23, 2014
Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trialViky Y Suncion, Eduard Ghersin, Joel E Fishman, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Journal of the American College of Cardiology|November 19, 2016
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM TrialJoshua M Hare, Darcy L DiFede, Angela C Rieger, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Behavioral Medicine (Washington, D.C.)|November 15, 2024
The Role of Intersectional Stigma in Coronary Artery Disease Among Cisgender Women Aging with HIVTiffany R Glynn, Michaela E Larson, Maria Bernal, et al.
JAMA|November 3, 2012
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trialJoshua M Hare, Joel E Fishman, Gary Gerstenblith, et al.
Circulation Research|January 23, 2014
Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trialViky Y Suncion, Eduard Ghersin, Joel E Fishman, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Journal of the American College of Cardiology|November 19, 2016
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM TrialJoshua M Hare, Darcy L DiFede, Angela C Rieger, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
Pageof 6